Active Biotech AB announced that the Board has appointed the company's current CSO Helén Tuves on as new CEO of the company. Helén Tuvesson will take up the position on July 1, 2017, replacing Tomas Leanderson, who has been the company's CEO since 2008. Helén Tuves on has a broad experience in drug development after more than 20 years in the pharmaceutical industry. Helén has held various senior positions in Active Biotech and since 2011 she has been responsible for the company's research and development.